122 related articles for article (PubMed ID: 35116079)
1. Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study.
Taxonera C; Martínez-Montiel MP; Barreiro-de-Acosta M; Vera I; Lorente R; Vega P; Diz-Lois MT; Fuentes Coronel AM; Pérez Calle JL; Casis B; Ferreiro-Iglesias R; Calvo M; Olivares D; Alba C
Therap Adv Gastroenterol; 2021; 14():17562848211056157. PubMed ID: 35116079
[TBL] [Abstract][Full Text] [Related]
2. No Difference of Adalimumab Pharmacokinetics When Dosed at 40 mg Every Week or 80 mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose Intensification.
Paul S; Williet N; Nancey S; Veyrard P; Boschetti G; Phelip JM; Flourie B; Roblin X
Dig Dis Sci; 2021 Aug; 66(8):2744-2749. PubMed ID: 32936345
[TBL] [Abstract][Full Text] [Related]
3. Treatment With Adalimumab 80 mg Every Other Week in Inflammatory Bowel Disease: Results of Treatment Intensification in Clinical Practice.
Calvo Moya M; González Lama Y; Ruíz Antorán B; Omella Usieto I; El Hajra Martinez I; Santos Pérez E; Menchén Viso B; Matallana Royo V; González Partida I; de Lucas Tellez de Meneses R; Bella Castillo P; González Rodriguez M; Vera Mendoza MI
Crohns Colitis 360; 2023 Jan; 5(1):otac051. PubMed ID: 36785555
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease.
Dubinsky MC; Rosh J; Faubion WA; Kierkus J; Ruemmele F; Hyams JS; Eichner S; Li Y; Huang B; Mostafa NM; Lazar A; Thakkar RB
Inflamm Bowel Dis; 2016 Apr; 22(4):886-93. PubMed ID: 26950307
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study.
Leonardi C; Sobell JM; Crowley JJ; Mrowietz U; Bao Y; Mulani PM; Gu Y; Okun MM
Br J Dermatol; 2012 Sep; 167(3):658-67. PubMed ID: 22564148
[TBL] [Abstract][Full Text] [Related]
6. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial.
Taxonera C; López-Sanromán A; Vera-Mendoza I; Domènech E; Ruiz VV; Marín-Jiménez I; Guardiola J; Castro L; Esteve M; Iglesias E; Ceballos D; Martínez-Montiel P; Gisbert JP; Mínguez M; Echarri A; Calvet X; Barrio J; Hinojosa J; Martín-Arranz MD; Márquez-Mosquera L; Bermejo F; Rimola J; Alba C; Pons V; Nos P;
Dig Liver Dis; 2019 Apr; 51(4):529-535. PubMed ID: 30712954
[TBL] [Abstract][Full Text] [Related]
7. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics.
Sandborn WJ; Colombel JF; Schreiber S; Plevy SE; Pollack PF; Robinson AM; Chao J; Mulani P
Inflamm Bowel Dis; 2011 Jan; 17(1):141-51. PubMed ID: 20848500
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis.
Chen X; Hou J; Yuan Y; Huang C; Liu T; Mo C; Li H; Chen B; Xu Q; Hou Z; He W; Liu F
BioDrugs; 2016 Jun; 30(3):207-17. PubMed ID: 27120055
[TBL] [Abstract][Full Text] [Related]
9. Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA.
Travis S; Feagan BG; Peyrin-Biroulet L; Panaccione R; Danese S; Lazar A; Robinson AM; Petersson J; Pappalardo BL; Bereswill M; Chen N; Wang S; Skup M; Thakkar RB; Chao J
J Crohns Colitis; 2017 Oct; 11(11):1317-1325. PubMed ID: 28981846
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life of patients with inflammatory bowel disease in Singapore.
Min Ho PY; Hu W; Lee YY; Gao C; Tan YZ; Cheen HH; Wee HL; Lim TG; Ong WC
Intest Res; 2019 Jan; 17(1):107-118. PubMed ID: 30419638
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB
Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379
[TBL] [Abstract][Full Text] [Related]
12. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease.
Sandborn WJ; Colombel JF; D'Haens G; Plevy SE; Panés J; Robinson AM; Pollack PF; Zhou Q; Castillo M; Thakkar RB
Curr Med Res Opin; 2013 May; 29(5):483-93. PubMed ID: 23438483
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy.
Motoya S; Watanabe M; Wallace K; Lazar A; Nishimura Y; Ozawa M; Thakkar R; Robinson AM; Singh RSP; Mostafa NM; Suzuki Y; Hibi T
Inflamm Intest Dis; 2018 Jul; 2(4):228-235. PubMed ID: 30221150
[TBL] [Abstract][Full Text] [Related]
14. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.
Ryan C; Sobell JM; Leonardi CL; Lynde CW; Karunaratne M; Valdecantos WC; Hendrickson BA
Am J Clin Dermatol; 2018 Jun; 19(3):437-447. PubMed ID: 29380251
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and clinical monitoring through posologic changes in adalimumab intensification regimen from 40 mg every week to 80 mg every other week.
Diz-Lois Palomares MªT; Porta Sánchez Á; Elberdin Pazos L; González Conde B; Outeda Macías M; Vázquez Rey MT; Estévez Prieto E; Martín Herranz I; Alonso Aguirre P
Rev Esp Enferm Dig; 2022 Dec; 114(12):708-712. PubMed ID: 35170328
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Controlled Trial of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD).
Cross RK; Langenberg P; Regueiro M; Schwartz DA; Tracy JK; Collins JF; Katz J; Ghazi L; Patil SA; Quezada SM; Beaulieu D; Horst SN; Russman K; Riaz M; Jambaulikar G; Sivasailam B; Quinn CC
Am J Gastroenterol; 2019 Mar; 114(3):472-482. PubMed ID: 30410041
[TBL] [Abstract][Full Text] [Related]
17. Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis.
Gniadecki R; Leonardi CL; Gordon KB; Gu Y; Geng Z; Nader A; Teixeira HD
J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1297-1304. PubMed ID: 29524255
[TBL] [Abstract][Full Text] [Related]
18. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial.
Irvine EJ; Zhou Q; Thompson AK
Am J Gastroenterol; 1996 Aug; 91(8):1571-8. PubMed ID: 8759664
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
Kimball AB; Kerdel F; Adams D; Mrowietz U; Gelfand JM; Gniadecki R; Prens EP; Schlessinger J; Zouboulis CC; van der Zee HH; Rosenfeld M; Mulani P; Gu Y; Paulson S; Okun M; Jemec GB
Ann Intern Med; 2012 Dec; 157(12):846-55. PubMed ID: 23247938
[TBL] [Abstract][Full Text] [Related]
20. Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.
Brandse JF; Vos LM; Jansen J; Schakel T; Ponsioen CI; van den Brink GR; D'Haens GR; Löwenberg M
J Crohns Colitis; 2015 Nov; 9(11):973-81. PubMed ID: 26116557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
